Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Non-Current Assets (2021 - 2025)

Summit Therapeutics (SMMT) has disclosed Other Non-Current Assets for 5 consecutive years, with $7.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets rose 277.56% year-over-year to $7.0 million, compared with a TTM value of $7.0 million through Sep 2025, up 277.56%, and an annual FY2024 reading of $2.5 million, down 41.05% over the prior year.
  • Other Non-Current Assets was $7.0 million for Q3 2025 at Summit Therapeutics, up from $6.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $7.0 million in Q3 2025 and bottomed at $140000.0 in Q3 2022.
  • Average Other Non-Current Assets over 5 years is $2.3 million, with a median of $1.9 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets skyrocketed 2994.29% in 2023, then tumbled 56.99% in 2024.
  • Year by year, Other Non-Current Assets stood at $170000.0 in 2021, then skyrocketed by 239.41% to $577000.0 in 2022, then soared by 649.05% to $4.3 million in 2023, then crashed by 41.05% to $2.5 million in 2024, then skyrocketed by 176.06% to $7.0 million in 2025.
  • Business Quant data shows Other Non-Current Assets for SMMT at $7.0 million in Q3 2025, $6.5 million in Q2 2025, and $4.1 million in Q1 2025.